You are here

  • Home
  • Archive
  • Volume 27, Issue 6
  • Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer

Citation Tools

Article menu
Download PDFPDF
Cervical Cancer
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Rosen VM, Guerra I, McCormack M, et al
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
International Journal of Gynecologic Cancer 2017;27:1237-1246.